Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NRIX Nurix Therapeutics

盘前交易 05-20 04:52:34 EDT

15.24

-0.27

-1.74%

盘前15.10

-0.14-0.92%

04:27 EDT

最高15.67	最低15.07	成交量106.04万
今开15.34	昨收15.51	日振幅3.87%
总市值15.76亿	流通市值13.16亿	总股本1.03亿
成交额1,621万	换手率1.23%	流通股本8,636万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":15.24,"timestamp":1779220800000,"preClose":15.51,"halted":0,"volume":1060387,"hourTrading":{"tag":"盘前","latestPrice":15.1,"preClose":15.24,"latestTime":"04:27 EDT","volume":27,"amount":405.620028,"timestamp":1779265624493,"change":-0.14,"changeRate":-0.009186,"amplitude":0.031496},"delay":0,"changeRate":-0.017408123791102487,"floatShares":86361800,"shares":103405813,"eps":-3.165026,"marketStatus":"盘前交易","change":-0.27,"latestTime":"05-20 04:52:34 EDT","open":15.34,"high":15.67,"low":15.07,"amount":16207506.30924,"amplitude":0.038685,"askPrice":17.04,"askSize":100,"bidPrice":13.76,"bidSize":18,"shortable":3,"etf":0,"ttmEps":-3.165026,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779283800000},"marketStatusCode":1,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":15.24,"preHourTrading":{"tag":"盘前","latestPrice":15.1,"preClose":15.24,"latestTime":"04:27 EDT","volume":27,"amount":405.620028,"timestamp":1779265624493,"change":-0.14,"changeRate":-0.009186,"amplitude":0.031496},"postHourTrading":{"tag":"盘后","latestPrice":15.69,"preClose":15.24,"latestTime":"18:33 EDT","volume":32400,"amount":494158.7853,"timestamp":1779230030827,"change":0.45,"changeRate":0.029528,"amplitude":0.045932},"volumeRatio":0.988720393334662,"impliedVol":0.37,"impliedVolPercentile":0.064},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"1155111507","title":"Nurix Therapeutics宣布Bexobrutideg将在2026年欧洲血液学协会大会进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1155111507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155111507?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:06","pubTimestamp":1778616379,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics宣布，其候选药物Bexobrutideg将在2026年欧洲血液学协会（EHA）大会上进行口头报告。这一进展标志着该药物在血液学领域的研究获得了重要认可，并将向全球血液学专家展示其最新的临床数据与研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614078037","title":"Nurix Therapeutics, Inc.盘中异动 急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614078037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614078037?lang=zh_cn&edition=full","pubTime":"2026-02-24 23:32","pubTimestamp":1771947122,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日23时32分，Nurix Therapeutics, Inc.股票出现异动，股价急速拉升5.07%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.19%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家临床阶段的生物制药公司，专注于发现、开发和潜在商业化靶向蛋白降解疗法，用于治疗癌症和炎症性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022423320397a6e2f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022423320397a6e2f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136327662","title":"Nurix Therapeutics公布2025财年第四季度及全年业绩，并更新公司战略进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1136327662","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136327662?lang=zh_cn&edition=full","pubTime":"2026-01-29 05:01","pubTimestamp":1769634074,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics近日披露了其2025财年第四季度及全年的财务业绩报告，同时向市场同步了公司最新的运营动态与发展规划。此次公告涵盖了公司在关键财务指标上的表现，并阐述了其在研发管线推进、战略合作深化等方面的最新情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103866902","title":"Nurix Therapeutics 将Bexobrutideg扩展至自身免疫及炎症适应症，计划2026年提交新片剂配方IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1103866902","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103866902?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:17","pubTimestamp":1768220237,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics 宣布将其在研药物Bexobrutideg的研发范围扩展至自身免疫性疾病和炎症性疾病的适应症领域。公司制定了明确的发展路线图，目标是在2026年向监管机构提交新片剂配方的临床试验申请（IND）。这一战略举措旨在探索该药物在更广泛疾病领域的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590395309","title":"Nurix Therapeutics股价大涨！旗下BTK降解剂bexobrutideg获积极试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395309","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395309?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:52","pubTimestamp":1765248777,"startTime":"0","endTime":"0","summary":"12月9日，美国生物制药公司$Nurix Therapeutics$周一报告了旗下药物bexobrutideg在治疗血液癌症上的积极试验数据。在1b期患者队列中，早期数据显示接受剂量为600mg的bexobrutideg治疗的患者ORR为83.3%。在上个月，Truist首予Nurix Therapeutics“买入”评级，目标价为30美元;BTIG则重申对Nurix Therapeutics的“买入”评级，目标价维持在27美元。根据17位分析师给出的12个月目标价，目前分析师们对对Nurix Therapeutics的平均目标价为27.18美元，最高目标价为41美元，最低目标价则为15美元。","market":"us","thumbnail":"https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/55eb327f580527889cf30bafa92692ae"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379154.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Nurix Therapeutics股价大涨！旗下BTK降解剂bexobrutideg获积极试验数据","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148020207","title":"Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨，接近一年高点，最后上涨20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148020207","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148020207?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:34","pubTimestamp":1765204452,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics股价因早期血癌药物试验数据大幅上涨，接近一年高点，最后上涨20.5%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153694626","title":"Nurix Therapeutics在第67届美国血液学会年会及展览会上发布Bexobrutideg (Nx-5948)在WaldenstrÖM巨球蛋白血症阶段1试验的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153694626","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153694626?lang=zh_cn&edition=full","pubTime":"2025-12-08 21:01","pubTimestamp":1765198874,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics在第67届美国血液学会年会及展览会上发布Bexobrutideg (Nx-5948)在WaldenstrÖM巨球蛋白血症阶段1试验的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188314236","title":"Nurix Therapeutics发布口服CBL-B抑制剂NX-1607首个人体临床试验的新转化数据，显示免疫激活与肿瘤微环境重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=1188314236","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188314236?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572107,"startTime":"0","endTime":"0","summary":"11月7日，Nurix Therapeutics Inc公布了口服CBL-B抑制剂NX-1607的首个人体临床试验的新转化数据，结果显示该药物具有免疫激活作用，并能重塑肿瘤微环境。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658359","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516658359?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:35","pubTimestamp":1741016156,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时35分，Nurix Therapeutics, Inc.股票出现异动，股价急速跳水5.18%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514331683","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514331683","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514331683?lang=zh_cn&edition=full","pubTime":"2025-02-28 01:39","pubTimestamp":1740677995,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日01时39分，Nurix Therapeutics, Inc.股票出现异动，股价大幅下跌5.10%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514726011","title":"Nurix Therapeutics, Inc.盘中异动 临近午盘股价大跌5.04%报16.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514726011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514726011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:38","pubTimestamp":1740501495,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时38分，Nurix Therapeutics, Inc.股票出现异动，股价大幅跳水5.04%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510353845","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.00%报17.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510353845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510353845?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:07","pubTimestamp":1739297270,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日02时07分，Nurix Therapeutics, Inc.股票出现波动，股价大幅下挫5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509231285","title":"Nurix Therapeutics, Inc.盘中异动 大幅上涨5.00%报19.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509231285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509231285?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:24","pubTimestamp":1738776295,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时24分，Nurix Therapeutics, Inc.股票出现异动，股价急速拉升5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.06%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508178878","title":"Nurix Therapeutics, Inc.盘中异动 临近收盘急速跳水5.07%报18.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178878","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508178878?lang=zh_cn&edition=full","pubTime":"2025-02-04 04:44","pubTimestamp":1738615480,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日04时44分，Nurix Therapeutics, Inc.股票出现波动，股价大幅跳水5.07%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507692295","title":"Nurix Therapeutics, Inc.2024财年实现净利润-1.94亿美元，同比减少34.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507692295","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507692295?lang=zh_cn&edition=full","pubTime":"2025-01-30 12:01","pubTimestamp":1738209666,"startTime":"0","endTime":"0","summary":"1月30日，Nurix Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.94亿美元，同比减少34.72%；其中营业收入为54.55百万美元，同比减少29.15%，每股基本收益为-2.88美元。机构评级：截至2025年1月30日，当前有17家机构对Nurix Therapeutics, Inc.目标价做出预测，其中目标均价为33.18美元，其中最低目标价为26.00美元，最高目标价为41.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507659941","title":"加拿大皇家银行：维持Nurix Therapeutics(NRIX.US)评级，由优于大市调整至优于大市评级, 目标价由26.00美元调整至27.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507659941","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507659941?lang=zh_cn&edition=full","pubTime":"2025-01-30 01:36","pubTimestamp":1738172215,"startTime":"0","endTime":"0","summary":"加拿大皇家银行：维持Nurix Therapeutics(NRIX.US)评级，由优于大市调整至优于大市评级, 目标价由26.00美元调整至27.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30013647899048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507398356","title":"小摩：维持Nurix Therapeutics(NRIX.US)评级，由增持调整至增持评级, 目标价由31.00美元调整至30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507398356","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507398356?lang=zh_cn&edition=full","pubTime":"2025-01-29 22:04","pubTimestamp":1738159446,"startTime":"0","endTime":"0","summary":"小摩：维持Nurix Therapeutics(NRIX.US)评级，由增持调整至增持评级, 目标价由31.00美元调整至30.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29220447898251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NRIX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507633778","title":"Stifel：维持Nurix Therapeutics(NRIX.US)评级，由买入调整至买入评级, 目标价由34.00美元调整至36.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507633778","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507633778?lang=zh_cn&edition=full","pubTime":"2025-01-29 21:22","pubTimestamp":1738156968,"startTime":"0","endTime":"0","summary":"Stifel：维持Nurix Therapeutics(NRIX.US)评级，由买入调整至买入评级, 目标价由34.00美元调整至36.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29212247898164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NRIX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507843680","title":"HC Wainwright & Co.：维持Nurix Therapeutics(NRIX.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至36.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507843680","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507843680?lang=zh_cn&edition=full","pubTime":"2025-01-29 20:20","pubTimestamp":1738153253,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Nurix Therapeutics(NRIX.US)评级，由买入调整至买入评级, 目标价由35.00美元调整至36.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29202047897457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507522389","title":"Nurix Therapeutics(NRIX.US)：2024年Q4财报实现营收1328.4万美元，前值为1515.9万美元，预期值为1285.9万美元；每股收益为-0.75美元，前值为-0.77美元，预期值为-0.71美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507522389","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507522389?lang=zh_cn&edition=full","pubTime":"2025-01-29 06:20","pubTimestamp":1738102841,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics(NRIX.US)：2024年Q4财报实现营收1328.4万美元，前值为1515.9万美元，预期值为1285.9万美元；每股收益为-0.75美元，前值为-0.77美元，预期值为-0.71美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29062047883837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NRIX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.0451},{"period":"1month","weight":-0.1296},{"period":"3month","weight":-0.0155},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.6025},{"period":"ytd","weight":-0.1966}],"compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.2335},{"period":"ytd","weight":0.076}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nurix Therapeutics, Inc.于2009年8月27日在特拉华州注册成立，总部位于加利福尼亚州布里斯班。它是一家临床阶段的生物制药公司，专注于靶向蛋白质降解药物的发现、开发和商业化，旨在改善癌症和炎症性疾病患者的治疗选择。在人工智能（AI）集成发现引擎和E3连接酶生物学深厚专业知识的支持下，该公司推进了将蛋白质降解科学转化为临床疗法的差异化方法。Nurix的全资管道包括针对布鲁顿酪氨酸激酶（BTK）和Casitas B系淋巴瘤原癌基因B（CBL-B）的研究候选药物，以及临床前开发中的额外降解剂和降解剂抗体偶联物。Nurix与包括吉利德科学、赛诺菲和辉瑞在内的全球制药合作伙伴合作，还根据共同开发和共同商业化安排，为多个候选药物开展发现计划。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.015258},{"month":6,"riseRate":0.6,"avgChangeRate":0.118065},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}